• Alias: ARRY-162; MEK162; ARRY-43162
    • An orally available inhibitor of MEK1/2 prevents the activation of MEK1/2-dependent effector proteins and transcription factors, which may result in the inhibition of growth factor–mediated cell signaling. This may eventually lead to an inhibition of tumor cell proliferation and an inhibition in the production of various inflammatory cytokines, including interleukin-1, -6, and tumor necrosis factor.
    • Phase 1/2 in combination with palbociclib in KRAS-mutated NSCLC; phase 3 in combination with irinotecan, encorafenib, cetuximab, and 5FU in BRAF V600E mutant mCRC
    • Recommended phase 2 dose: 45 mg PO b.i.d. til disease progression
    Other topics in Targeted and Immunotherapy Agents